BMS 866949

Drug Profile

BMS 866949

Alternative Names: BMS-866949

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AMRI
  • Class Antidepressants
  • Mechanism of Action Biogenic amine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Sweden (PO)
  • 26 Mar 2012 Bristol-Myers Squibb terminates a phase I trial in volunteers in Sweden (NCT01124344)
  • 31 Jul 2009 Phase-I clinical trials in Major depressive disorder in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top